Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Daily

Download Data

Edgewise Therapeutics Inc Price to Book Ratio (P/B) on June 03, 2024: 3.04

Edgewise Therapeutics Inc Price to Book Ratio (P/B) is 3.04 on June 03, 2024, a 68.26% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Edgewise Therapeutics Inc 52-week high Price to Book Ratio (P/B) is 5.86 on February 07, 2024, which is 92.91% above the current Price to Book Ratio (P/B).
Edgewise Therapeutics Inc 52-week low Price to Book Ratio (P/B) is 0.00 on May 06, 2024, which is -99.85% below the current Price to Book Ratio (P/B).
Edgewise Therapeutics Inc average Price to Book Ratio (P/B) for the last 52 weeks is 2.62.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends